Dalpiciclib free base
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 535189

CAS#: 1637781-04-4 (free base)

Description: Dalpiciclib, also known as SHR-6390, is a cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. SHR6390 exhibited potent antiproliferative activity against a wide range of human RB‐positive tumor cells in vitro, and exclusively induced G1 arrest as well as cellular senescence, with a concomitant reduction in the levels of Ser780‐phosphorylated RB protein. Compared with the well‐known CDK4/6 inhibitor palbociclib, orally administered SHR6390 led to equivalent or improved tumor efficacy against a panel of carcinoma xenografts, and produced marked tumor regression in some models, in association with sustained target inhibition in tumor tissues. Furthermore, SHR6390 overcame resistance to endocrine therapy and HER2‐targeting antibody in ER‐positive and HER2‐positive breast cancer, respectively. Moreover, SHR6390 combined with endocrine therapy exerted remarkable synergistic antitumor activity in ER‐positive breast cancer.


Chemical Structure

img
Dalpiciclib free base
CAS# 1637781-04-4 (free base)

Theoretical Analysis

MedKoo Cat#: 535189
Name: Dalpiciclib free base
CAS#: 1637781-04-4 (free base)
Chemical Formula: C25H30N6O2
Exact Mass: 446.24
Molecular Weight: 446.555
Elemental Analysis: C, 67.24; H, 6.77; N, 18.82; O, 7.17

Price and Availability

Size Price Availability Quantity
10mg USD 250 2 Weeks
25mg USD 450 2 Weeks
50mg USD 750 2 Weeks
100mg USD 1350 2 Weeks
200mg USD 2350 2 Weeks
Bulk inquiry

Related CAS #: 1980822-14-7 (Isethionate)   1637781-04-4 (free base)    

Synonym: SHR-6390; SHR6390; SHR 6390; Dalpiciclib;

IUPAC/Chemical Name: 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperidin-4-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one

InChi Key: SGJLSPUSUBJWHO-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H30N6O2/c1-15-20-14-28-25(29-21-8-7-18(13-27-21)17-9-11-26-12-10-17)30-23(20)31(19-5-3-4-6-19)24(33)22(15)16(2)32/h7-8,13-14,17,19,26H,3-6,9-12H2,1-2H3,(H,27,28,29,30)

SMILES Code: O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(C4CCNCC4)C=C3)N=C2N1C5CCCC5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 446.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Yin Y, Shi Y, Pan Y, Wang Y, Xie W, Yan M, Liu Y, Yan P, Wu F, Zhu X, Zou J; DAWNA-1 Study Consortium. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021 Nov;27(11):1904-1909. doi: 10.1038/s41591-021-01562-9. Epub 2021 Nov 4. PMID: 34737452.


2: Niu N, Qiu F, Xu Q, He G, Gu X, Guo W, Zhang D, Li Z, Zhao Y, Li Y, Li K, Zhang H, Zhang P, Huang Y, Zhang G, Han H, Cai Z, Li P, Xu H, Chen G, Xue J, Jiang X, Jahromi AH, Li J, Zhao Y, de Faria Castro Fleury E, Huo S, Li H, Jerusalem G, Tripodi D, Liu T, Zheng X, Liu C. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple- positive breast cancer. Nat Commun. 2022 Nov 17;13(1):7043. doi: 10.1038/s41467-022-34838-w. PMID: 36396665; PMCID: PMC9672048.


3: Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y, Teng Y, Yan X, Wang Y, Xie W, Zeng X, Wang X, Hu C, Geng C, Zhang H, Li W, Wu X, Zhong J, Xu J, Shi Y, Wei W, Bayaxi N, Zhu X, Xu B. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo- controlled, phase 3 trial. Lancet Oncol. 2023 Jun;24(6):646-657. doi: 10.1016/S1470-2045(23)00172-9. Epub 2023 May 11. PMID: 37182538.


4: Chen X, Shen K. Dalpiciclib in advanced breast cancer. Lancet Oncol. 2023 Jun;24(6):578-579. doi: 10.1016/S1470-2045(23)00228-0. PMID: 37269836.


5: Dalpiciclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer. Oncologist. 2021 Jul;26 Suppl 3(Suppl 3):S9-S10. doi: 10.1002/onco.13865. Epub 2021 Jun 21. PMID: 34152061; PMCID: PMC8262302.


6: Bu J, Zhang Y, Niu N, Bi K, Sun L, Qiao X, Wang Y, Zhang Y, Jiang X, Wang D, Ma Q, Li H, Liu C. Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer. Elife. 2023 Jan 5;12:e85246. doi: 10.7554/eLife.85246. PMID: 36602226; PMCID: PMC9822241.


7: Zhang J, Meng Y, Wang B, Wang L, Cao J, Tao Z, Li T, Yao W, Hu X. Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. Front Oncol. 2022 Mar 7;12:775081. doi: 10.3389/fonc.2022.775081. PMID: 35321427; PMCID: PMC8936075.


8: Hindié E. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy. Lancet Oncol. 2023 Sep;24(9):e356. doi: 10.1016/S1470-2045(23)00360-1. PMID: 37657471.


9: Xu B. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author's reply. Lancet Oncol. 2023 Sep;24(9):e357. doi: 10.1016/S1470-2045(23)00361-3. PMID: 37657472.


10: Zhang P, Xu B, Gui L, Wang W, Xiu M, Zhang X, Sun G, Zhu X, Zou J. A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomark Res. 2021 Apr 12;9(1):24. doi: 10.1186/s40364-021-00271-2. PMID: 33845905; PMCID: PMC8042970.


11: Tao Y, Li T, Lin P, Jiang X, Shi P, Fu Y, Liu X, Wang C, Li S, Li X, Cao Y. A Randomized, Open-Label, Phase I Clinical Study of Dalpiciclib With Different Specifications After Process Modification in Healthy Chinese Volunteers. Clin Pharmacol Drug Dev. 2023 Jan;12(1):65-69. doi: 10.1002/cpdd.1182. Epub 2022 Oct 26. PMID: 36285519.


12: Zhang H, Yan S, Zhan Y, Ma S, Bian Y, Li S, Tian J, Li G, Zhong D, Diao X, Miao L. A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans. Front Pharmacol. 2023 Mar 31;14:1116073. doi: 10.3389/fphar.2023.1116073. PMID: 37063263; PMCID: PMC10102643.


13: Sheikh MS, Satti SA. The emerging CDK4/6 inhibitor for breast cancer treatment. Mol Cell Pharmacol. 2021;13(3):9-12. PMID: 35251463; PMCID: PMC8896653.


14: Ge R, Wang BY, Jiang ZF; Expert Group of Chinese Society of Clinical Oncology Breast Cancer. [Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer]. Zhonghua Zhong Liu Za Zhi. 2022 Dec 23;44(12):1296-1304. Chinese. doi: 10.3760/cma.j.cn112152-20220825-00578. PMID: 36575782.


15: Zhao S, Zhang H, Yang N, Yang J. A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer. Transl Cancer Res. 2023 Jun 30;12(6):1617-1634. doi: 10.21037/tcr-22-2807. Epub 2023 Jun 15. PMID: 37434680; PMCID: PMC10331716.


16: Nabieva N, Fasching PA. CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers (Basel). 2023 Mar 14;15(6):1763. doi: 10.3390/cancers15061763. PMID: 36980649; PMCID: PMC10046117.


17: Han L, Wang N, Li Y, Jiang S, Gu Y. A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature. Ann Transl Med. 2022 Dec;10(24):1413. doi: 10.21037/atm-22-5201. PMID: 36660646; PMCID: PMC9843329.


18: Pan B, Hao Z, Xu Y, Wang Z, Yao R, Wang X, Ren C, Zhou Y, Sun Q, Huo L. Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient. Front Oncol. 2022 Dec 23;12:1095779. doi: 10.3389/fonc.2022.1095779. PMID: 36620595; PMCID: PMC9816999.